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Abstract 
 
Mutations in the GAA gene may cause a late onset Pompe disease presenting with proximal weakness without the characteristic muscle 
pathology, and therefore a test for GAA activity is the first tier analysis in all undiagnosed patients with hyperCKemia and/or limb-girdle 
muscular weakness. By using MotorPlex, a targeted gene panel for next generation sequencing, we analyzed GAA and other muscle disease-
genes in a large cohort of undiagnosed patients with suspected inherited skeletal muscle disorders (n = 504). In this cohort, 275 patients 
presented with limb-girdle phenotype and/or an isolated hyperCKemia. Mutational analysis identified GAA mutations in ten patients. Further 
seven affected relatives were identified by segregation studies. All the patients carried the common GAA mutation c.-32-13T >G and a second, 
previously reported mutation. In the subcohort of 275 patients with proximal muscle weakness and/or hyperCKemia, we identified late-onset 
Pompe disease in 10 patients. The clinical overlap between Pompe disease and LGMDs or other skeletal muscle disorders suggests that GAA 
and the genes causing a metabolic myopathy should be analyzed in all the gene panels used for testing neuromuscular patients. However, 
enzymatic tests are essential for the interpretation and validation of genetic results.   
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1. Introduction 
 
Glycogen storage disease II or Pompe disease (MIM 
232300) is an autosomal recessive disorder caused by mu-
tations in the GAA gene (MIM 606800), encoding alpha-1,4-
glucosidase, a lysosomal enzyme involved in the degradation 
of glycogen [1,2].  
Depending on the level of residual enzymatic activity, mu-
tations in GAA lead to a wide spectrum of clinical phenotypes, 
ranging from a severe infantile form, presenting with car-
diomyopathy and muscular hypotonia, to a relatively milder, 
late onset form of Pompe disease (LOPD), characterized by a 
slowly progressive proximal muscle weakness, often involv-
ing the respiratory muscles [3–5].  
The diagnosis of LOPD is challenging and is usually 
achieved with significant delay. LOPD patients, in fact, may 
exhibit a mild phenotype, partially overlapping that of other 
neuromuscular disorders (NMDs) [2,6]. Moreover, the 
histopathological findings are often unspecific, given the fact 
that often neither glycogen storage nor vacuoles are present in 
LOPD muscle biopsies [7,8]. The clinical overlap with other 
disorders and the misleading histological features often ham-
per an early diagnosis at onset of the symptoms, resulting in a 
diagnostic odyssey [6,8].  
The measurement of GAA activity, usually on a dried blood 
spot (DBS), serves as diagnostic screening test [9], al-though 
the results must be confirmed by a second biochem-ical assay 
on different tissues as skeletal muscle, fibroblasts or 
leucocytes and corroborated by the presence of two GAA 
pathogenic mutations [10,11].  
A disease-specific treatment, the enzyme replacement ther-
apy (ERT), is available since 2006. However, ERT has a lim-
ited effect on LOPD patients [12]. Early diagnosis and the 
subsequent early initiation of therapy may have an impact on 
the therapeutic success, preventing severe muscular and 
respiratory impairment [6].  
In recent years, the development of cutting-edge technolo-
gies has revolutionized the diagnostic approach to the genetic 
disorders [13]. Different NGS approaches for the diagnosis of 
patients with skeletal muscle diseases have been described in 
literature [14]. In particular, targeted resequencing (TGS) of 
specific genes of interest represents a cost-effective strategy 
for the clinical diagnostics of heterogeneous disorders [14,15].  
In this manuscript, we describe clinical and morphologi-cal 
data of 16 LOPD patients identified by performing Mo-
torPlex, an NGS-based platform to analyze genes associated 
with skeletal muscle disorders, with subsequent segregation 
analysis in a large cohort of myopathy patients. 
 
 
 
 
 
 
 
2. Materials and methods 
 
DNA samples from 504 patients with a broad range of 
myopathies, including LGMDs, congenital myopathies, distal 
myopathies, and isolated hyperCKemia, were recruited in the 
network of the Italian Association of Myology. Patients were 
clinically evaluated by neurologists within tertiary care cen-
ters for neuromuscular disorders and had remained without 
final diagnosis. For each patient, clinical history and labora-
tory data were collected in a specific form. Patients signed a 
written informed consent at the time of blood collection. The 
study was approved by the Ethics Committee of Univer-sità 
degli Studi della Campania “Luigi Vanvitelli” and was 
performed according to the Declaration of Helsinki.  
Genomic DNA was extracted from peripheral blood by 
phenol/chloroform extraction. All the samples were enriched 
using MotorPlex [16,17], a custom assay to analyze a panel of 
genes causing neuromuscular disorders. All the enrichments 
were performed according to manufacturer’s instructions (Ag-
ilent Technologies, Santa Clara, CA, USA). Each library was 
run on a HiSeq 1000 (Illumina).  
An in-house pipeline [18] was used to analyze the raw se-
quencing data generated. All the variants were confirmed by 
Sanger sequencing using an ABI PRISM 3130 XL automatic 
DNA Sequencer Genetic Analyzer (Applied Biosystems, Fos-
ter City, CA, USA).  
A segregation analysis was performed according to the 
availability of DNA from relatives.  
A biochemical test evaluating the GAA activity was per-
formed, when possible, on samples from patients with GAA 
mutations. GAA activity in skeletal muscle, DBS and lympho-
cytes was assessed by a fluorometric method using the sub-
strate 4-methylumbelliferyl-α-D-glucoside [19]. The newly 
diagnosed LOPD patients were re-assessed, re-evaluating the 
clinical presentation, functional measures (6 minute walking 
test, 6MWT), creatine kinase levels and respiratory functions 
(forced vital capacity, FVC, in supine and/or seated position).  
We performed a copy number variant (CNV) analysis by 
using a custom array-CGH, MotorChip (Agilent Technolo-
gies) [20]. 
 
3. Results 
 
Sixteen patients from nine unrelated families were diag-
nosed with LOPD (patient II has been extensively described 
elsewhere [21]). All patients showed the common c.-32-13T 
>G variant [22] and a second, already reported, mutation on 
the other allele [23–27] (Table 1). In particular, the sec- 
  
 
Table 1  
Patients with late-onset pompe disease.  
 
Case Onset Age at Symptoms at onset  Last assessment     Genotype (NG_009822.1 or NM_000152.3) 
 
  diagnosis (y)              
 
                
 
   Limb Resp. Other 6MWT Plasma CK FVC seated ml Histology GAA activity  1st allele 2nd allele 
 
   weak.   (mt)  (%N)  (pmol/min/mg)     
 
              
 
I early 49 prox. no fatigability n.a. 5–10× n.a. myopathic lymphocytes: 14.2 c.784G >A;p.E262K c.-32-13T >G [18] 
 
 adul.           [23]   
 
II
∗ adul. 71 prox. no myalgia 40 5–10× 850 (22%) myopathic DBS: 0 c.1564C >G;p.P522A   
 
            [27]   
 
III adul. 63 prox. and no fatigability, n.a. 2.5–5× n.a. myopathic muscle: 11.7  c.1927G >A;p.G643R   
 
   dist.  dysphagia       [25]   
 
IV,1 early 40 prox. yes exercise n.a. 2.5–5× n.a. vacuoles n.a.  c.1124G >T;p.R375L   
 
 adul.    intolerance       [24]   
 
IV,2 early 47 prox. yes  n.a. 2.5–5× n.a. n.a. n.a.     
 
 adul.               
 
IV,3 early 50 not no  n.a. 2.5–5× n.a. n.a. n.a.     
 
 adul.  observed             
 
IV,4 early 45 prox. no  n.a. 2.5–5× n.a. vacuoles n.a.     
 
 adul.               
 
V,1 adol. 42 prox. no fatigability, 135 5–10× 950 (20%) vacuoles DBS: 0.20  c.1124G >T;p.R375L   
 
     myalgia       [24]   
 
V,2 adul. 33 prox. no fatigability 566 5–10× 3000 (90%) n.a. DBS: 0.20     
 
V,3 child. 45 prox. no n.a.   2.5–5× n.a. n.a. DBS: 0.08  
c.2237G >A;p.W746
∗ 
  
 
VI,1 early 63 prox. and yes fatigability, n.a. normal 1520 (38%) n.a. DBS: 0.24    
 
 adul.  axial  myalgia       [26]   
 
VI,2 adul. 61 prox. yes fatigability 418 2.5–5× 2040 (46%) myopathic DBS: 0.22     
 
VI,3 adul. 64 prox. yes  n.a. 2.5–5× 1550 (48%) n.a. DBS: 0.16     
 
VII adol. 33 prox. and no cramps n.a. 2.5–5× 5260 (112%) vacuoles DBS: 0.20 c.784G >A;p.E262K   
 
   dist.         [23]   
 
VIII early 56 prox. no fatigability, 385 2.5–5× 2480 (75%) myopathic DBS: 0.13 c.G989A;p.W330
∗
  [27]   
 
 adul.    myalgia           
 
IX early n.a. prox. yes fatigability, WCB n.a. n.a. n.a. n.a.  c.1124G >T;p.R375L   
 
 adul.    cardiac       [24]   
 
     involvement           
  
y = years; Resp. = respiratory; 6MWT = 6 minutes walking test; N = normal; adult. = adulthood; child. = childhood; adol. = adolescence; prox. = proximal; dist. 
= distal; n.a. = not available; DBS = dried blood spot; CK = creatine kinase; FVC = forced vital capacity; WCB = Wheel-chair-bound.  
∗  Patient II has been described in full elsewhere [21]. 
 
ond allele carried a missense change in seven families and a 
nonsense variant in the remaining two families.  
Among LOPD patients, there were more men (10/16, 
62.5%) than women (6/16, 37.5%), with a male to female sex 
ratio of 1.66. Adult onset was observed in almost all patients 
(13/16, 81.2%), except patients V,1 and VII who showed their 
first symptoms during adolescence and patient V,3 who had a 
childhood onset.  
The symptoms at onset were mainly proximal weakness 
(12/16, 75%), and fatigability (10/16, 62.5%). Exercise intol-
erance, myalgia and contractures were less common in this 
cohort; some of the patients showed dysphagia. None of the 
patients had central nervous system involvement at onset; the 
heart was affected in only one patient with an early adult 
presentation. Respiratory involvement was observed during 
the first visit in six patients (37.5%). Increased creatine ki-
nase levels (2.5–10× the upper normal limit) were observed in 
14 patients. When performed (6 cases), electromyography 
showed a myopathic pattern. Muscle biopsy, performed in 9 
patients, showed presence of vacuoles in only four patients.  
The mean age of the patients was 50.8 ± 11.7 years (range 
33–71). The average diagnostic delay was 21.5 years (range = 
11–38). Two patients used a wheelchair at the time of latest 
evaluation. GAA enzymatic activity, tested in 11 patients 
 
 
(9 through DBS, 1 each in muscle and lymphocytes) was re-
duced in all samples, confirming the diagnosis of LOPD.  
A marked inter- and intrafamiliar phenotypic variabilities 
were observed. The presence of a nonsense variant (families 
VI and IIX) in trans with the common c.-32-13T >G variant 
did not correlate with either a more severe phenotype or an 
earlier onset of the disease.  
Our screening also identified five patients (three affected 
by LGMD and two by a congenital myopathy), carrying the 
c.-32-13T >G variant in heterozygosity. In two of them the 
identification of already described mutations addressed the 
diagnosis toward a different disease (LGMD2C and nema-line 
myopathy 1). In the three remaining patients, no other 
causative variants in GAA were identified and a custom array-
CGH [20] excluded the presence of any copy number variants 
affecting this gene in two of the patients (the third patient was 
not tested because of DNA unavailability). Unfortunately the 
loss to follow-up of these patients did not allow us to perform 
any biochemical test to evaluate the GAA activity. 
 
4. Discussion 
 
We analyzed GAA together with all other genes included in 
the MotorPlex [15,16] in 504 genetically undiagnosed pa- 
   
 
Table 2        
 
Broadening the spectrum of clinical phenotypes associated with metabolic myopathies by next generation sequencing.   
 
       
 
Reference Genetic approach Cohort Results Atypical elements   
 
        
 
Ghaoui et al. [32] WES LGMD (n = 60) 1 GAA∗ n.a.   
 
   1 CPT2 fixed weakness   
 
  
LGMD (n = 38) 
1 PYGM fixed weakness   
 
Todd et al. [33] WES 1 GBE fetal akinesia and multiple pterygium syndrome 
 
Lévesque et al. [34] Targeted resequencing Muscle Disorders (n = 34) 1 GAA long lasting history of gait disturbances   
 
Kuhn et al. [35] Targeted resequencing LGMD (n = 58) 1 GBE minimal non-lysosomal glycogen storage   
 
  
LGMD (n = 55) 
  without any evidence of polyglucosan bodies   
 
Reddy et al. [36] WES 1 GAA n.a.   
 
  
LGMD and/or hyperCKemia (n = 606) 
1 VCP    
 
Johnson et al. [37] WES 8 GAA n.a.   
  
n.a. = not available; WES = whole exome sequencing.  
∗  LOPD patient was identified in a pre-NGS screening. 
 
 
tients who presented a wide spectrum of clinical phenotypes, 
ranging from isolated hyperCKemia to mild or severe mus-
cular impairment, and a variable age of onset and disease 
progression [16]. Two-hundred-seventy-five patients (in 259 
families), presenting with a limb-girdle muscular dystrophy 
(LGMD) and/or an isolated hyperCKemia, constituted a risk 
group for LOPD.  
Within this subgroup, we identified ten patients in nine 
families carrying GAA mutations consistent with a diagnosis 
of LOPD. Seven affected relatives were subsequently iden-
tified by segregation analyses in these families. This corre-
sponds to a prevalence of LOPD of 3.63% (10/275) in the 
undiagnosed patients with adult onset proximal weakness or 
hyperCKemia. As expected, no bi-allelic causative GAA vari-
ants were identified among patients with other phenotypes 
such as, congenital myopathies, congenital dystrophies, dis-tal 
myopathies, etc. Screening projects for Pompe disease by 
using DBS, in cohorts with similar phenotypes have been per-
formed previously, achieving a similar results [9,28–30], the 
only exception is Finland where Pompe disease is extremely 
rare [31] due to lack of endemic founder mutations. Several 
factors have hampered an early diagnosis in all the reported 
cases. First, muscle biopsy showed not specific myopathic 
aspects in most cases. Second, the loss to follow-up of the 
patients for many years excluded an early detection of res-
piratory symptoms critical to raise the clinical suspicion of 
LOPD. Third, in most patients, the clinical presentation in-
cluding atypical signs, e.g. dysphagia in patient III, pseudo-
hypertrophy in patient VII or calf hypertrophy in patient VIII, 
was probably misleading. In patient I, a previous western blot 
analysis had showed a reduction of calpain 3 (CAPN3), and 
Sanger sequencing of CAPN3 only revealed a heterozygous 
causative missense variant. At that time, the molecular find-
ings may suggest the presence of a second elusive mutation, 
corroborating the preliminary diagnosis of LGMD2A. How-
ever, this patient was included in the study, because this sec-
ond variant was truly absent from mRNA sequencing. This 
confirms that any genetic report should be very cautious in 
similar cases. Similarly, reduced staining for dystrophin in 
patient VIII suggested Becker dystrophy. 
 
 
 
On the other hand, currently NGS-based strategies are 
largely adopted to study genetically heterogeneous conditions, 
including muscle diseases [14]. Recent NGS data prove that 
20%–30% of myopathic patients carry causative mutations in 
genes typically not associated with the observed pheno-type 
[16,32–34]. Many studies [32–37] identified mutations in 
genes responsible for LOPD and other metabolic myopathies 
in patients with a wide range of phenotypes (Table 2). At the 
same time, a well-known homozygous mutation in ANO5, re-
sponsible for a wide spectrum of disorders described under the 
umbrella term “anoctaminopathy” [38,39], was identified in a 
patient suspected of having glycogen storage disease be-cause 
of the presence of glycogen containing vacuoles on muscle 
biopsy [40].  
The decreasing cost and the technological improvements 
will make NGS approaches an effective first tier screening 
method in the near future [41,42]. Given the large hetero-
geneity of neuromuscular disorders and the increasing number 
of associated genes, Mendeliome or whole exome sequenc-ing 
are advisable. However, the genetic analysis has to be 
included within a standardized diagnostic algorithm compris-
ing exhaustive clinical, histological and imaging tests which 
are essential for a proper interpretation of molecular findings. 
Consequently, biochemical assays, including DBS, and pro-
tein studies will remain essential for the interpretation and val-
idation of genetic results [34]. Above all, tests for acid alpha-
glucosidase activity are still the gold standard tests when clin-
icians suspect a Pompe disease in a patient. A smart, com-
bined use of these tests and NGS will allow a rapid diagnosis 
and, thereby, an early initiation of available treatments. 
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